Eatontown, NJ (August 16, 2018) – Hikma Pharmaceuticals USA Inc., a wholly owned subsidiary of Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), today announced the appointment of Kristy Ronco as Executive Vice President, Sales and Marketing for its Generics Division. Ms. Ronco will be responsible for leading Generics’ retail sales, addiction therapy sales and branded sales teams. She will also oversee marketing, pricing, forecasting and analytics.
16 August 2018
Corporate, Press Release
“Kristy is a talented leader with significant pharmaceutical industry experience across sales, marketing, operations, market analysis, contracts and pricing, and we are delighted she is joining our team,” said Brian Hoffmann, President of Hikma’s Generics Division. “I am looking forward to working closely with Kristy and her team to deliver substantial value to our customers, employees and the broader communities we serve.”
Ms. Ronco joins Hikma after 11 years at Zydus Pharmaceuticals where she was most recently Senior Vice President, Sales and Marketing. Earlier in her career, she held successive positions of increasing responsibility in marketing, contracts, pricing and market analysis at TEVA, Sandoz, Aventis and Johnson & Johnson. Ms. Ronco is also a registered nurse with extensive clinical patient-care experience across a range of medical disciplines and specialties.
”I am thrilled to be joining Hikma’s Generics business and look forward to helping the company fulfill its vital mission of producing and distributing high-quality generic medicines that each day put better health within reach of millions of people,” said Ms. Ronco.